SCHEMBL3013264

SCHEMBL3013264

Cc1cc(C)c(C)c(S(=O)(=O)C2CCN(c3nc(-c4ccccc4)cs3)CC2)c1C

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.51
AR P10275 3/20 0.51
TP53 P04637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX15 P16050 1/20 0.51
RAB9A P51151 9/20 0.50
NPC1 O15118 7/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 3/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 1/20 0.48
RECQL P46063 1/20 0.48
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012471 0.92 SMN1; SMN2 (0.57) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3012661 0.91 SMN1; SMN2 (0.48) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL15671709 0.90 MAPT (0.52) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3012627 0.89 MAPK1 (0.56) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3017277 0.89 SMN1; SMN2 (0.46) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3009737 0.88 SMN1; SMN2 (0.46) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3021185 0.88 SMN1; SMN2 (0.45) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3011770 0.88 MAPK1 (0.47) MAPK1LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3013205 0.88 SMN1; SMN2 (0.58) MAPK1LMNASMN1; SMN2ARTP53
SCHEMBL3008287 0.87 MAPT (0.56) MAPK1LMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885LMNA 80/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.